


**Clinical Trial**    *REVIVE-CLI*  
**Presenter -**    *Jim Goodrich*  
**PI -**            *William Marston, MD and Richard Powell, MD*  
**Sponsor -**      *Aastrom Biosciences, Inc.*

	<b>VASCULAR, NON-CARDIAC</b>	<b>CARDIAC</b>
<b>Target population</b>	<div style="display: flex; justify-content: space-around; border-top: 1px solid black; border-bottom: 1px solid black; padding: 5px 0;"> <span>Critical limb ischemia, Claudication</span> <span>Atherosclerosis, Restenosis</span> <span>Pulmonary</span> </div> <div style="text-align: center; margin-top: 10px;">  </div>	<div style="display: flex; justify-content: space-around; border-top: 1px solid black; border-bottom: 1px solid black; padding: 5px 0;"> <span>Acute MI</span> <span>Chronic angina</span> <span>Congestive heart failure</span> </div>
<b>Progenitor cell, biologic</b>	<i>Autologous Bone marrow derived</i>	
<b>Delivery method</b>	<i>IM</i>	
<b>Study Phase</b>	<i>3</i>	
<b>Primary objective</b>	<i>Safety, Efficacy – Amputation Free Survival</i>	
<b>Design</b>	<i>+ Randomized, + Controlled, + Placebo</i>	
<b># Clinical sites</b>	<i>80</i>	
<b><a href="http://www.ClinTrials.gov">www.ClinTrials.gov</a></b>	<i>NCT01483898</i>	

Clinical Trial - *REVIVE-CLI*  
Target enrollment - *594*  
Start date, End date *February 2012, March 2015*

## Study Flow and Current Enrollment

**0** enrolled

+ Randomized

Day 0

ixmyelocel-T (297)

Control (297)

Day/month 12  
1° efficacy & safety

# Patients

# Patients

Day/month 18  
final safety

# Patients

# Patients

Status: **Not yet enrolling**